After over three decades of research, an effective anti-HIV vaccine remains elusive. 55 Unconventional and novel vaccine strategies are needed. Here, we report that a vaccine focusing 56 the immune response on the sequences surrounding the 12 viral protease cleavage sites (PCSs) 57 provides greater than 80% protection of Mauritian cynomolgus macaques (MCMs) against 58 repeated intravaginal SIVmac251 challenges. The PCS-specific T cell responses are correlated 59 with vaccine efficacy. The PCS vaccine does not induce immune activation and inflammation 60 known to be associated with increased susceptibility to HIV infection. Machine learning analyses 61 revealed that the immune environment generated by the PCS vaccine predicts vaccine efficacy. 62 Our study demonstrates for the first time that a novel vaccine which targets viral maturation, but 63 lacks full Env and Gag proteins as immunogens, can prevent intravaginal infection in a highly 64 stringent NHP/SIV challenge model. Targeting HIV maturation thus offers a novel approach to 65 developing an effective HIV vaccine. 66 67 68
Introduction
HIV mutates rapidly and preferentially infects activated CD4+ T cells. Inflammation activates and 70 attracts HIV target cells, thereby enhancing the risk of infection 1-3 . These inherent characteristics of HIV 71 infection underscore the greater challenges compared to other pathogens when developing a 72 prophylactic vaccine 4,5 . Among the six HIV vaccine clinical efficacy trials to date, only the RV144 Thai 73 trial demonstrated any efficacy, and it was modest (31.2%) 4,6 . Since activated CD4 T cells are 74 preferential targets for HIV-1, an effective HIV vaccine would need to elicit protective anti-HIV 75 immunity while minimizing vaccine-induced inflammation and immune activation 5,7,8 . Our previous 76 studies of HIV highly exposed seronegative (HESN) Kenyan female sex workers showed that narrowly 77 targeted T cell responses were associated with protection against HIV infection [8] [9] [10] . Thus, an alternative 78 strategy for an effective HIV vaccine would be to generate immune response only to the essential part of 79 HIV-1 8,11 . Learning from natural immunity observed in these Kenyan HESN women, we tested a novel 80 strategy by focusing the host immune response on the sequences surrounding the 12 viral protease 81 whether continued challenges can lead to infection of the two uninfected control animals and to 116 determine the numbers of challenges needed to infect 50% of the vaccinated animals because of 117 biological variations among the monkeys, we extend the challenges to thirteen times (Table S3 ). 118 Following the extended challenges three additional animals in the PCS vaccine group became infected 119 (after 9, 11 and 13 challenges, respectively). However, the two previously uninfected control animals 120 remained uninfected (Table S3 ). This observation was consistent with findings from several previous 121 studies in rhesus macaques that a proportion of control animals were refractory to acquisition of 122 SIV/SHIV infections [28] [29] [30] [31] [32] [33] [34] [35] [36] . 123 Survival analysis demonstrated that the PCS vaccine significantly increased the number of challenges 124 required for acquisition of SIVmac251 infection (p = 0.046, log-rank test) (Fig. 1C ). It provided an 125 80.3% reduction in the per-exposure risk of viral acquisition (vaccine efficacy, VE = 1 -hazard ratio) 126 (proportional hazards regression) ( Figure 1C ). Furthermore, while it took only two SIVmac251 127 challenges to infect 50% animals in the control group ( Figure 1C and 1D ), extended challenges showed inflammation following vaccination. The vaccine-induced mucosal inflammation was analyzed by 139 quantifying inflammatory cytokine responses in cervicovaginal lavage (CVL) samples (Figure 2 A-G 140 and Figure S3 ). Thirteen pro-inflammatory cytokines (TNF-α, IFN-γ, IL-6, RANTES/CCL5, GM-CSF, 141 IL-1β, MCP-1/CCL2, IL-8, MIP-1α/CCL3, MIP-1β/CCL4, IP-10/CXCL10, IL-17A and IL-1α) and one 142 anti-inflammatory cytokine (IL-10) were analyzed. Vaccine-induced fold changes in cytokine levels at 143 multiple time points were determined and shown as heat maps (Figure 2A ). No apparent induction of 144 inflammatory cytokine responses, apart from some sporadic fluctuations, was observed in the control or 145 the PCS vaccine group. The short SIV PCS peptide immunogens in the PCS vaccine did not lead to the 146 persistent increase in cervicovaginal inflammatory responses in the PCS vaccine group in comparison to 147 the control group, except an initial increase after prime in IFN-γ, IL-6, RANTES, GM-CSF, MCP-1, and 148 IL-17A, which were dampened at later boost points (Figure 2A The PCS vaccine induced antibody and cellular responses 155 Mucosal antibodies to PCS peptide antigens were measured in CVL (reported previously) 12 and plasma 156 samples ( Figure S4A and Fig. S5 ). The patterns of anti-PCS peptide antibody (IgG) responses in CVL challenge plasma samples of the PCS vaccine group did not have neutralizing activities against tier 1 163 and tier 2 SIVmac251 (data not shown). The moderate magnitude of anti-PCS antibodies may reflect the 164 existence of B cell epitopes in the sequences surrounding the PCS, and indicate that immunization with 165 the PCS vaccine was effective in inducing antibodies to the PCS peptides. However, the contribution of 166 these antibodies to the protection is currently unknown. 167 To examine cellular immune responses, peripheral blood mononuclear cells (PBMCs) from the "peak" 168 time point were quantified by ELISPOT for frequency of IFNγ-producing cells in response to a pool of 169 SIV peptide antigens (PCS1-4, PCS5-8 or PCS9-12) ( Figure S4 B-D). Slightly higher numbers of 170 animals in the PCS vaccine group than those in the control group showed above background responses 171 to PCS5-8 and PCS9-12 peptide pools, but these differences were not statistically significant ( Figure S4 172 B-D). Although IFNγ ELISPOT has been traditionally used to evaluate T cell responses to vaccines, 173 many cytokines other than IFNγ are known to be secreted by activated T cells 40-42 . Thus, simply 174 assessing the IFNγ response by ELISPOT may give a very limited view of vaccine-induced T cell 175 responses 43 . Furthermore, in some vaccine studies, IFNγ secretion was a poor correlate of protection 176 against HIV, and was not the best indicator of vaccine-induced responses 43 . We therefore expanded the 177 analysis of cellular responses by measuring 14 cytokines using our customized Bio-Plex multiplexed 178 cytokine assay. 179 PBMCs of the PCS vaccine group from the "peak" time point were stimulated with PCS peptide pools 180 and quantified for cytokines secreted into the culture supernatants (Table S6 ). Between nine to fourteen 181 cytokines were detected following stimulations with different PCS peptide pools (PCS1-4: nine 182 cytokines, PCS5-8 and PCS9-12: fourteen cytokines). Among these cytokines, IFNγ was at a low level 183 and detectable only in less than half of the animals. Six other cytokines, including RANTES, MIP-1α, 184 MIP-1β, TNF-α, IL-6 and IL-8, were detected in 50% or higher percentage of animals (Table S6) 48 , which could play a role in regulating antiviral response. In summary, these data indicated that 191 several types of cellular immune responses to PCS antigens can be generated following vaccination. 193 194 We characterized the T cell subsets after immunization with the PCS vaccine. PBMCs from week 90 (a Figure 3E ). These suggest that the monkeys of the PCS vaccine group had an overall lower 207 level of immune activation. 208 After PCS peptide stimulation the monkeys in the PCS vaccine group had a lower frequency of 209 CD4 + CCR7 -CD45RA + terminal effector CD4 T cells (CD4 + T EMRA ) cells ( Figure 4A ). While the surface 210 expression of CD45RA on CD4 + T EMRA , and CCR7 expression on CD4 + CCR7 + CD45RA -T central 211 memory (CD4 + T CM ) were significantly higher in the PCS vaccine group ( Figure 4B, 4C ). The PCS-212 vaccinated animals also had lower CD107a expression in naive CD4+CCR7+CD45RA+ T cells (CD4+ 213 Tnaive) ( Figure 4D ), but significantly higher frequency of CD8 + CCR7 + CD45RA -T central memory 214 cells (CD8 + T CM ) ( Figure 4E ) and higher proportions of them expressing CD107a ( Figure 4F ). However, 215 the PCS-vaccinated monkeys had fewer CD8 + T CM cells expressing IFN-γ + ( Figure 4G ). 216 Thus, the frequency of PCS specific CD4 + T EM was low, but the surface expression of CD45RA on 217 CD4 + T EMRA cells and CCR7 on CD4 + T CM cells were higher in the PCS vaccine group. Consistent with 218 lower immune activation status, the PCS peptide specific CD4+ T naive cells of the PCS vaccine group 219 had lower level of CD107a expression. The higher frequency and higher expression level of CD107a+ 220 CD8 + T CM cells in the PCS vaccine group demonstrated that immunization with the PCS vaccine 221 generated PCS specific CD8+ central memory T cells that have better potential in killing viral infected 222 cells. 223 We conducted phenotypic analysis of Th17 and CD8+Th17 cells that were considered to be susceptible 241 We conducted regression analysis to identify potential immunologic factors that might be positively 242 correlated with protection against acquisition of SIVmac251 infection in the vaccinated group. We for multiple inference) were also identified, including CVL mucosal IL-1α level at the peak and pre-260 challenge time points, CVL mucosal antibodies to PCS1, 3, 4, 5 and 9 at the peak time point, as well as 261 the frequency or intensity of several activation or differentiation makers on subsets of CD4 + or CD8 + 262 memory, IL17A + or Treg cells at the pre-challenge time point (Table S7 ). These CoRs appear to relate to 263 inflammation, immune activation and SIV target cell availability. 264 To explore more potential CoP/CoRs, especially combinations of immunological predictors which might 265 act together to protect the vaccinated animals, we performed a multiple regression analysis of the 266 immunological data using the LASSO (least absolute shrinkage and selection operator) ( Figure 5 ). 267 Although the risk of overfitting is large, and R 2 optimistic (R 2 = 0.964) in this situation, the LASSO 268 regression model has nevertheless identified 6 potential predictors from pre-challenge T cell subsets, 5 269 of which were not identified via the single predictor Spearman correlation analysis ( Figure 5A , 5B and 270 Table S8 ). Individually these predictors also positively correlated with many other immunological 271 variants by Spearman rank correlation analysis ( Figure 5C and Table S8 ). The three predictors with was also confirmed in our study. Therefore, using the weekly challenge protocol, an infection identified 433 during a later challenge round may actually have been acquired in an earlier round, leading to an over-434 estimation of vaccine efficacy. In this regard, we carried out challenges every two weeks, and plasma 435 VL was quantified on days 6, 10 and 14 of each challenge round (any animal found infected was not 436 challenged further). Indeed, we found that in some cases an infection could remain below detectable 437 level until as late as 14 days following a challenge (Table S3 ). In addition, we took into consideration that in females, susceptibility to vaginal HIV infection could be affected by phases of the menstrual 439 cycle. It was reported that the susceptibility is higher in the luteal phase than in non-luteal phases 110-114 .
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The PCS vaccine generated fewer viral target cells and higher PCS peptide specific CD8 + T memory
and CD4 + T reg responses
Immunologic correlates of protection (CoPs) induced by vaccination
440
Our 2-week challenge cycle was also designed to maximize the chance for even distribution of 
